CME/CE Activity

The National Kidney Foundation (NKF) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), an accredited provider by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation, an accredited provider by the Commission on Dietetic Registration (CDR) and an accredited provider by the Association for Social Work Boards (ASWB) to provide continuing education to physicians, nurses/dialysis technicians, dietitians and social workers respectively. In addition, individual activities are approved on an activity specific basis for family physicians, advanced practitioners (nurse practitioners and physician assistants), pharmacists, certified case managers, transplant coordinators, and other specialties.

System Requirements for Participation

Challenges in Lipid Management: Addressing the High-Risk Patient and the Potential for Novel Therapies (A Knowledge-based Program)

Available through: Feb 27, 2017

This CME/CE Activity will address clinical gaps and barriers to optimal lipid management, and how to manage high-risk patients. An overview of research on novel therapies, such as PCSK9 inhibitors, will also be discussed. This activity will include online slide presentations with 3-D animated simulation segments to actively educate and engage participants.

Upon completion of this educational activity, you will be able to:

Identify barriers to optimize lipid management strategies in high-risk patients receiving medication, including heterozygous familial hypercholesterolemia, chronic kidney disease, and statin intolerance.

Recognize how to analyze research while incorporating evidence-based guidelines on novel lipid lowering treatments (PCSK9 inhibition and others), mechanisms of action, and clinical trial data.

Approved for: 1.0 **
Faculty: Martin Quan, MD, Karol E. Watson, MD, PhD, Christie M. Ballantyne, MD

NKF Kidney Talks Video Series

Available through: Aug 15, 2016

This CME/CE NKF Kidney Talks Learning Activity enables the participant to learn from renowned speakers through short, visually engaging animated presentations. This program is comprised of three stand-alone video presentations that inform clinicians of current science about treating proteinuria as it relates to membranous nephropathy.

The overall goal of this program is to:

Review current research and clinical findings regarding the pathogenesis of membranous nephropathy

Examine novel and effective tools for diagnosing and monitoring membranous nephropathy, thus providing guidance for the best treatment course

Identify the most current therapeutic options for membranous nephropathy, thus promoting individualized patient care

Membranous Nephropathy: New Insights Regarding Pathogenesis

Membranous Nephropathy: New Insights Regarding Diagnosis

Membranous Nephropathy: New Insights Regarding Treatment

Approved for: Each course is approved for .25 **
Faculty: Laurence H. Beck, Jr., MD, PhD; Fernando C. Fervenza, MD, PhD

Heart-Kidney Interaction & the Role of Vasopressin and Hyponatremia in Heart Failure

Available through: Aug 15, 2016

This program will address the common medical problem of hyponatremia in heart failure (HF), and its clinical management in the presence of kidney disease. Content will review mechanistic responses to disequilibrium in the heart-kidney interaction that lead to alterations in water and sodium balance, the role of vasopressin in the pathogenesis of hyponatremia, and the relationship between hyponatremia and mortality risk. Expert faculty will address differential diagnosis, evaluation and treatment of hyponatremia in HF patients, and will provide insight into clinical evidence for available treatment options, including the benefits and limitations of vasopressin receptor antagonists.

Approved for: 1.5 **
Faculty: Mathew R. Weir, MD; Joseph G. Verbalis, MD; James E. Udelson, MD

Clinical Aspects of Fibroblast Growth Factor 23 in Chronic Kidney Disease

Available through: Aug 15, 2016

This program will provide current information about the emerging clinical significance of fibroblast growth factor 23 (FGF23), a major modifier of bone mineral metabolism. Studies linking FGF23 to adverse renal and cardiovascular outcomes in patients with chronic kidney disease (CKD) will be discussed.

Approved for: 1.5 **
Faculty: Csaba P. Kovesdy, MD, FASN; Myles S. Wolf, MD, MMSc; Orlando M. Gutierrez, MS, MMSc

New Insights Into the Role of Phosphorus Balance in Chronic Kidney Disease

Available through: Aug 15, 2016

This program will improve learners’ strategies for managing serum phosphorus and anemia in patients with chronic kidney disease (CKD) or kidney failure.

Approved for: 1.5 **
Faculty: Myles S. Wolf, MD, MMSc; Geoffrey A. Block, MD, CCRI; Sylvia E. Rosas, MD, MSCE, FNKF

Hemoglobin Variability: Individualization of Anemia Management for the Patient with End Stage Renal Disease

Available through: Sep 15, 2015

This program will review the evaluation and management of hemoglobin variability in patients with dialysis-related anemia. Strategies to optimize and individualize anemia therapy for patients on dialysis will be discussed.

Approved for: 1.5 **
Faculty: Anil K. Agarwal, MD, FACP, FASN, FN; Lynda Szczech, MD; Jay B. Wish, MD

Approaches to Membranous Nephropathy

Available through: Sep 15, 2015

This web-based program will help participants:
1) Review current research and clinical findings in the pathophysiology of membranous nephropathy (MN).
2) Examine novel diagnostic tools and management options in membranous lupus nephropathy (MLN) in order to differentiate MLN from the other glomerular diseases, and to understand its unique requirements.
3) Identify current therapeutic options in MN in order to individualize patient care with the most appropriate regimen.

Approved for: 1.5 **
Faculty: Fernando C. Fervenza, MD, PhD, FNKF; Joanne M. Bargman, MD, FRCPC; Laurence Beck, Jr., MD, PhD

A New Era In PKD Management: Strategies In Delaying Progression

Available through: Sep 15, 2015

This activity will actively engage learners in evaluating their knowledge of and practice in polycystic kidney disease (PKD), identifying areas for improvement, and planning to make positive changes to delay disease progression and improve outcomes.

Approved for: 1.5 **
Faculty: Charles L. Edelstein, MD, PhD, FAHA; Arlene Chapman, MD; Benjamin D. Cowley, Jr., MD

Expert Perspectives in the Management of Bone-Mineral-Vascular Disorders: A Pathophysiological and Evidence-Based Approach to Care

Available through: Aug 15, 2015

This program will focus on the pathophysiologic consequences of CKD-related mineral and bone abnormalities, as well as their relationships to CV risk and the other comorbidities. Strategies to optimize management of CKD-MBD via dietary and treatment intervention will be explored in detail.

Approved for: 1.5 **
Faculty: Kathleen M. Hill Gallant, PhD, RD, Ellie Kelepouris, MD, FAHA, Mathew R. Weir, MD

Persistent Hyperuricemia: A Multi-Pronged Approach to the Management of Serum Urate Levels in Chronic Kidney Disease

Available through: Aug 15, 2015

This program will discuss the pathophysiology and diagnosis of gout and the influence of chronic kidney disease (CKD) in its presentation and management, as well as demonstrate the application of the American College of Rheumatology (ACR) Clinical Practice Guidelines for optimizing patient care in the setting of CKD.

Approved for: 1.5 **
Faculty: Louis Kuritzky, MD; Robert Terkeltaub, MD; Jay B. Wish, MD

Journal of Renal Nutrition (JRN) Online CPE Program

Available through:
Each article is valid for credit for 2 years from original posting.
A monthly series of CPE activities based on a single article published in the Journal of Renal Nutrition (JRN).
Approved for: 2.0 **
Faculty: Varies